FDA Panel Gives Thumbs Down To Sarepta Duchenne Muscular Dystrophy Drug Eteplirsen

Sarepta, a pharmaceutical company that develops RNA-based treatments, fell short of providing substantial evidence that eteplirsen is effective in treating Duchenne muscular dystrophy. The gruelling 11-hour session was attended by patients, their families and drug advocacy groups.